HOUSTON, Oct. 10,
2022 /PRNewswire/ -- CNS Pharmaceuticals,
Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a
biopharmaceutical company specializing in the development of novel
treatments for primary and metastatic cancers in the brain and
central nervous system, today announced that John Climaco, Chief Executive Officer of CNS
Pharmaceuticals, will participate in The American Brain Tumor
Association's Breakthrough for Brain Tumors® 5K Run taking place Saturday, November 5, 2022 in Los Angeles, CA.
![(PRNewsfoto/CNS Pharmaceuticals, Inc.) (PRNewsfoto/CNS Pharmaceuticals, Inc.)](https://mma.prnewswire.com/media/1120277/CNS_Pharmaceuticals_Logo.jpg)
"The unmet need in brain tumor treatment is immense and knows no
geographic borders. As CEO of CNS I have come to know many brain
tumor patients personally and the optimism and strength with which
they have all faced this terrible diagnosis is a continuing source
of inspiration to me. Supporting these patients, their journey and
the challenges they currently endure is not just a priority for us,
it is why we do what we do," commented John
Climaco, CEO of CNS Pharmaceuticals. "Across the globe there
is an urgent need for safe and effective GBM treatment options, and
I am proud to participate in the BT5K to support the mission of the
ABTA, to help bring hope to patients and families and to raise much
needed funds for research."
The American Brain Tumor Association's BT5K offers the
opportunity to support the ABTA mission to advance the
understanding and treatment of brain tumors with the goals of
improving, extending and, ultimately, saving the lives of those
impacted by a brain tumor diagnosis.
As part of participating in the event, donations are being
accepted to further research which can benefit all patients and
provide critical funding for brain tumor research and for
supporting patient care. If you would like to make a donation,
please visit here.
About CNS Pharmaceuticals, Inc.
CNS Pharmaceuticals a clinical-stage pharmaceutical company
developing a pipeline of anti-cancer drug candidates for the
treatment of primary and metastatic cancers of the brain and
central nervous system. The Company's lead drug candidate,
Berubicin, is a novel anthracycline and the first anthracycline to
appear to cross the blood-brain barrier. Berubicin is currently in
development for the treatment of a number of serious brain and CNS
oncology indications including glioblastoma multiforme (GBM), an
aggressive and incurable form of brain cancer.
Additionally, the Company is advancing the development of
its WP1244 drug technology portfolio, which utilizes anthracycline
and distamycin-based scaffolds to create small molecule agents and
is believed to be 500x more potent than daunorubicin in inhibiting
tumor cell proliferation. Preclinical studies of WP1244
demonstrated high uptake in the brain with antitumor activity. CNS
Pharmaceuticals is evaluating the use of the WP1244 portfolio in
the treatment of brain cancers, pancreatic, ovarian, and
lymphomas.
For more information, please visit www.CNSPharma.com, and
connect with the Company on Twitter, Facebook, and LinkedIn.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/cns-pharmaceuticals-to-participate-in-the-american-brain-tumor-associations-breakthrough-abta-for-brain-tumors-5k-bt5k-run-301644341.html
SOURCE CNS Pharmaceuticals, Inc.